Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

TNFRSF13B

Introduction

Tumor necrosis factor receptor superfamily, member 13B, also known as TNFRSF13B, is a human gene.[1]

The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17.[1]

References

References

  1. ↑ 1.0 1.1 “Entrez Gene: TNFRSF13B tumor necrosis factor receptor superfamily, member 13B”.
Further reading

Further reading

  • Bossen C, Schneider P (2007). “BAFF, APRIL and their receptors: structure, function and signaling”. Semin. Immunol. 18 (5): 263–75. doi:10.1016/j.smim.2006.04.006. PMID 16914324.
  • Treml LS, Crowley JE, Cancro MP (2007). “BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells”. Semin. Immunol. 18 (5): 297–304. doi:10.1016/j.smim.2006.07.001. PMID 16919470.
  • Mackay F, Leung H (2007). “The role of the BAFF/APRIL system on T cell function”. Semin. Immunol. 18 (5): 284–9. doi:10.1016/j.smim.2006.04.005. PMID 16931039.
  • Salzer U, Jennings S, Grimbacher B (2007). “To switch or not to switch–the opposing roles of TACI in terminal B cell differentiation”. Eur. J. Immunol. 37 (1): 17–20. doi:10.1002/eji.200636914. PMID 17171762.
  • Maruyama K, Sugano S (1994). “Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides”. Gene. 138 (1–2): 171–4. PMID 8125298.
  • von Bülow GU, Bram RJ (1997). “NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily”. Science. 278 (5335): 138–41. PMID 9311921.
  • Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K; et al. (1997). “Construction and characterization of a full length-enriched and a 5′-end-enriched cDNA library”. Gene. 200 (1–2): 149–56. PMID 9373149.
  • Gross JA, Johnston J, Mudri S; et al. (2000). “TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease”. Nature. 404 (6781): 995–9. doi:10.1038/35010115. PMID 10801128.
  • Xia XZ, Treanor J, Senaldi G; et al. (2000). “TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation”. J. Exp. Med. 192 (1): 137–43. PMID 10880535.
  • Yan M, Marsters SA, Grewal IS; et al. (2001). “Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity”. Nat. Immunol. 1 (1): 37–41. doi:10.1038/76889. PMID 10881172.
  • Marsters SA, Yan M, Pitti RM; et al. (2000). “Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI”. Curr. Biol. 10 (13): 785–8. PMID 10898980.
  • von Bülow GU, Russell H, Copeland NG; et al. (2000). “Molecular cloning and functional characterization of murine transmembrane activator and CAML interactor (TACI) with chromosomal localization in human and mouse”. Mamm. Genome. 11 (8): 628–32. PMID 10920230.
  • Wu Y, Bressette D, Carrell JA; et al. (2001). “Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS”. J. Biol. Chem. 275 (45): 35478–85. doi:10.1074/jbc.M005224200. PMID 10956646.
  • Yu G, Boone T, Delaney J; et al. (2001). “APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity”. Nat. Immunol. 1 (3): 252–6. doi:10.1038/79802. PMID 10973284.
  • Strausberg RL, Feingold EA, Grouse LH; et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932.
  • Novak AJ, Darce JR, Arendt BK; et al. (2004). “Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival”. Blood. 103 (2): 689–94. doi:10.1182/blood-2003-06-2043. PMID 14512299.
  • Ota T, Suzuki Y, Nishikawa T; et al. (2004). “Complete sequencing and characterization of 21,243 full-length human cDNAs”. Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
  • Hymowitz SG, Patel DR, Wallweber HJ; et al. (2005). “Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding”. J. Biol. Chem. 280 (8): 7218–27. doi:10.1074/jbc.M411714200. PMID 15542592.
  • Moreaux J, Cremer FW, Reme T; et al. (2005). “The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature”. Blood. 106 (3): 1021–30. doi:10.1182/blood-2004-11-4512. PMID 15827134.
  • Castigli E, Wilson SA, Garibyan L; et al. (2005). “TACI is mutant in common variable immunodeficiency and IgA deficiency”. Nat. Genet. 37 (8): 829–34. doi:10.1038/ng1601. PMID 16007086.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.